We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Archemix Corp. announced today a multi-year, multi-product alliance with Elan Corporation, plc focused on the discovery, development, and commercialization of first-in-class aptamer therapeutics to treat autoimmune disease.
Caraco Pharmaceutical Laboratories, Ltd., announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Glipizide tablets.
Drugmaker Stada Arzneimittel AG said Thursday it struck a deal to sell its stake in an American subsidiary for $40 million and plans to exit the U.S. market completely.
Parker & Waichman, LLP announced that it has filed suit against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc., on behalf of the estate of a 26-year-old woman.
Americans are increasingly distrustful of clinical research information from pharmaceutical companies, a trend that may be impeding the trial process, experts say.
Tercica moved one step closer to prevailing in a patent dispute when a federal court determined that several companies had infringed on its patent for Increlex, a growth hormone.
More venture capital-backed biotech firms could become eligible for federal research funding under a compromise being worked out by Senate Republicans.
Salix Pharmaceuticals, Ltd. announced that the company has entered into an agreement with Cedars-Sinai Medical Center, (CSMC), for the right to use US Patent No. 6,861,053 and US Patent Application No. 11/234,516 relating to methods of diagnosis and treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth.